Heron Therapeuti (HRTX)

NASDAQ
2.71
+0.04(+1.50%)
After Hours
2.70
-0.01(-0.37%)
- Real-time Data
  • Volume:
    2,215,835
  • Day's Range:
    2.63 - 2.77
  • 52 wk Range:
    2.19 - 9.45

HRTX Overview

Prev. Close
2.67
Day's Range
2.63-2.77
Revenue
77.65M
Open
2.68
52 wk Range
2.19-9.45
EPS
-2.07
Volume
2,215,835
Market Cap
322.19M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,554,502
P/E Ratio
-1.33
Beta
0.878
1-Year Change
-67.24%
Shares Outstanding
118,888,122
Next Earnings Date
Feb 23, 2023
What is your sentiment on Heron Therapeuti?
or
Market is currently closed. Voting is open during market hours.

Heron Therapeuti News

Heron Therapeuti Analysis

Heron Therapeuti Company Profile

Heron Therapeuti Company Profile

Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralBuySellStrong Sell
Technical IndicatorsStrong SellNeutralSellStrong SellStrong Sell
SummaryStrong SellNeutralNeutralStrong SellStrong Sell
  • BEST BEAR PROMOTION!!!
    0
    • !!!! Heron's stock rises after FDA approval of surgical medicine
      0
      • Can this go back to 30 dollars?
        0
        • Strong squeeze play candidate with prices consolidating and a recent pocket pivot. A lot of large players seem to be buying in. #Bullish
          0
          • Target price seems 32$ in 12 months? Do you agree?
            0
        • $HRTX has all 9 analyst saying “BUY” with an ave 12 month target price of $37.33 which is 144% ROI at is closing price of $15.28
          1
          • Still sluggish
            0